Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Sonoma Pharmaceuticals Inc(SNOA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SNOA
11/12/2026: SNOA (1-star) is currently NOT-A-BUY. Pass it for now.
Sonoma Pharmaceuticals is a micro-cap specialty firm focused on hypochlorous acid-based dermatology and wound care products. The company's main strength lies in its proprietary Microcyn technology, which offers a non-toxic alternative to traditional infection management. Its primary growth story revolves around expanding its presence in the animal health market and securing international partnerships to drive revenue. However, the company faces significant risks from stiff competition by large pharmaceutical incumbents, persistent operational losses, and historical dependence on equity dilution. Sonoma is best suited for risk-tolerant investors looking for exposure to niche medical technology who are willing to monitor the efficacy of its commercial execution closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company lacks consistent, accelerating revenue growth required by most growth investors. |
| Momentum investor | Weak fit | The stock lacks sustained positive price momentum or volume support for trend following. |
| Value investor | Weak fit | Persistent operating losses make traditional valuation multiples difficult to justify. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for operations. |
| Low-risk investor | Weak fit | High volatility and operational uncertainty make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock exhibits significant price swings due to low float and speculative market interest. |
| Valuation risk | High | Investors face risk due to the gap between current market cap and operational cash flow generation. |
| Competition risk (Large Pharma) | High | Large incumbents with deeper resources can easily outspend or undercut Sonoma on price. |
| Business quality | Medium | While the technology is innovative, the business model has struggled to achieve scale. |
| Dividend income | Low / none | There is no income component to the investment thesis. |
| Execution risk | Medium / high | The management team must successfully navigate complex regulatory and distribution landscapes. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.94M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 54.4K shares | Beta 1.31 | 52 Weeks Range 0.85 - 3.95 | Updated Date 11/12/2026 |
52 Weeks Range 0.85 - 3.95 | Updated Date 11/12/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -56.78% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Dermatology and Wound Care | Sale of proprietary Microcyn-based topical gels and liquids for wound and skin management. | Revenue comes from selling high-margin, specialized medical liquids that treat skin conditions. |
| Animal Health | Veterinary-focused products under the MicrocynAH brand for animal wound care. | The company captures a secondary revenue stream by repurposing its core technology for pet care. |
| Licensing and Royalties | Agreements with third-party partners to distribute products in international territories. | The company generates supplemental income by allowing other firms to sell its products globally. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-10 | When - | Estimate - | Actual 0.09 |
Profitability
Profit Margin -7.65% | Operating Margin (TTM) -3.32% |
Management Effectiveness
Return on Assets (TTM) -3.15% | Return on Equity (TTM) -34.54% |
Valuation
Trailing PE - | Forward PE 46.08 | Enterprise Value 1.63M | Price to Sales(TTM) 0.25 |
Enterprise Value 1.63M | Price to Sales(TTM) 0.25 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 11.46 | Shares Outstanding 4.79M | Shares Floating 5.04M |
Shares Outstanding 4.79M | Shares Floating 5.04M | ||
Percent Insiders 0.39 | Percent Institutions 2.67 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.